Dezecapavir
Based on 1 Customer Validation
Dezecapavir (VH-499) is a HIV-1 capsid protein inhibitor. Dezecapavir exhibits picomolar-level antiviral activity against a variety of HIV-1 laboratory strains and clinical isolates in vitro. Dezecapavir inhibits the early and late stages of the HIV-1 life cycle, blocking nuclear import, reverse transcript production, virion assembly, maturation, and post-nuclear import/pre-integration replication processes. Dezecapavir can be used in studies related to HIV-1 infection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.97%
- CAS No.: 2568911-72-6
- Formule: C37H29ClF9N9O5S
- Masse moléculaire:918.19
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
HIV-1 |
Dezecapavir (0-4 days) inhibits the replication of HIV-1 NLRepRluc-WT in MT-2 cells, with a mean EC50 of 0.023 nM and extremely low cytotoxicity (CC50 >20 μM)[2].
Dezecapavir inhibits the replication of multiple HIV-1 laboratory strains in A3R5-GFP/Luc cells, with a mean EC50 of 0.042 nM[2].
Dezecapavir (0-72 h) potently inhibits the early (EC50 0.036 nM) and late (EC50 0.50 nM) stages of HIV-1 replication in a two-cell assay system, and reduces viral p24 release from HEK 293T cells with an IC50 of 1.2 nM[2].
Dezecapavir (50 nM; 96 h post-infection) blocks HIV-1 replication in MT-2 cells after reverse transcription is completed but before proviral integration, as evidenced by its time-of-addition inhibition curve[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2568911-72-6
-
Appearance Solid
-
Masse moléculaire 918.19
-
Formule C37H29ClF9N9O5S
-
Color White to off-white
-
SMILES
FC(F)(CCOC1=NC(N=C(N(C2=O)C3=C(N(N=C4NS(C)(=O)=O)C)C4=C(C=C3)Cl)[C@@H](NC(CN5C6=C(C(C(F)F)=N5)[C@]7([H])[C@@](C(F)6F)([H])C7)=O)CC8=CC(F)=CC(F)=C8)=C2C=C1)F
-
Synonyms
VH-499; VH4011499
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : ≥ 100 mg/mL (108.91 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Thakkar N, et al. Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV. Infect Dis Ther. 2025;14(5):1011-1025. [Content Brief]
[2]. Wang C, et al. Preclinical virology profiles of the HIV-1 capsid inhibitors VH4004280 and VH4011499. Antimicrob Agents Chemother. 2025;69(10):e0030925. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0891 mL | 5.4455 mL | 10.8910 mL | 27.2275 mL |
| 5 mM | 0.2178 mL | 1.0891 mL | 2.1782 mL | 5.4455 mL | |
| 10 mM | 0.1089 mL | 0.5445 mL | 1.0891 mL | 2.7227 mL | |
| 15 mM | 0.0726 mL | 0.3630 mL | 0.7261 mL | 1.8152 mL | |
| 20 mM | 0.0545 mL | 0.2723 mL | 0.5445 mL | 1.3614 mL | |
| 25 mM | 0.0436 mL | 0.2178 mL | 0.4356 mL | 1.0891 mL | |
| 30 mM | 0.0363 mL | 0.1815 mL | 0.3630 mL | 0.9076 mL | |
| 40 mM | 0.0272 mL | 0.1361 mL | 0.2723 mL | 0.6807 mL | |
| 50 mM | 0.0218 mL | 0.1089 mL | 0.2178 mL | 0.5445 mL | |
| 60 mM | 0.0182 mL | 0.0908 mL | 0.1815 mL | 0.4538 mL | |
| 80 mM | 0.0136 mL | 0.0681 mL | 0.1361 mL | 0.3403 mL | |
| 100 mM | 0.0109 mL | 0.0545 mL | 0.1089 mL | 0.2723 mL |
Dezecapavir Related Classifications
HY-159828 Related Classifications
Powered by Bioz